Climb Bio, Inc. (CLYM) Stock Price & Analysis
Climb Bio, Inc. (CLYM) closed at USD 10.91 on Thursday, October 15, 2026, up 6.03% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.29; the Oct 15, 2026 session ranged USD 10.25–10.98 on volume of 515,484 shares. Market capitalization is $626.63M, with a 52-week range of USD 1.64–18.33 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLYM.md
Key facts (CLYM)
- Analysts: Buy (mean 1.87 on a 1–5 scale) (15 analysts), mean target USD 27.57 (range 18–40).
- Total return with dividends: 1Y +459.5% vs S&P 500 +18.1%; 5Y -32.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD -0.19, revenue estimate $0K.
Analysts (CLYM)
Consensus Buy (mean 1.87 on a 1–5 scale), 15 analysts; mean target USD 27.57 (low 18, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | Oppenheimer | Target raised | Outperform | $18 → $25 |
| 2026-09-08 | HC Wainwright & Co. | Target raised | Buy | $24 → $30 |
| 2026-09-04 | B. Riley Securities | Target raised | Buy | $26 → $30 |
| 2026-09-03 | BTIG | Target raised | Buy | $20 → $32 |
| 2026-09-03 | Baird | Target raised | Outperform | $21 → $25 |
| 2026-08-24 | HC Wainwright & Co. | Target raised | Buy | $20 → $24 |
| 2026-08-19 | Wedbush | Reiterated | Outperform | $20 |
| 2026-08-07 | Truist Securities | Target raised | Buy | $17 → $25 |
| 2026-07-27 | Wedbush | Target raised | Outperform | $17 → $20 |
| 2026-06-24 | HC Wainwright & Co. | Reiterated | Buy | $20 |
Total return (dividends reinvested) (CLYM)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +459.5% | -32.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +462.8% | -7.5% |
| Volatility (annualized) | 92.0% | 101.2% |
| Max drawdown | -42.3% (Aug 2026→Oct 2026) | -93.7% (Oct 2021→Mar 2025) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 10.91 |
|---|---|
| Change | ▲ 6.03% (up) |
| Previous Close | USD 10.29 |
| Open | USD 10.32 |
| Day Range | USD 10.25 – 10.98 |
| 52-Week Range | USD 1.64 – 18.33 |
| Volume | 515,484 shares |
| Market Cap | $626.63M |
| Exchange | NGM |
Technical Analysis (CLYM)
Nexqual's technical model rates CLYM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.37 (neutral) |
| vs SMA50 | Below (USD 13.78) |
| MACD | -0.91 (negative) |
Analyst Ratings (CLYM)
Wall Street analysts rate CLYM "Buy" based on 15 analysts, with a mean price target of USD 27.57 (range USD 18–40), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 27.57 |
| High Target | USD 40 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (CLYM)
| Next Earnings Date | 2026-11-13 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.21 ▲ beat |
| 2026-03-31 | USD -0.2 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.21 ▼ miss |
| 2025-09-30 | USD -0.19 vs est -0.15 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (CLYM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -27.10% |
| Debt / Equity | 0.01 |
| Current Ratio | 31.45 |
| Total Cash | $183.12M |
| Total Debt | $1.31M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (CLYM)
Nexqual rates Climb Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $183M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$53M (TTM) |
| Efficiency | Critical — ROE -27%, ROA -18.5% |
Ownership (CLYM)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +105.62% |
| Shares Outstanding | 57.44M |
| Float | 38.74M |
| Short % of Float | +23.86% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (CLYM)
Climb Bio, Inc. is led by Aoife M. Brennan BAO, BCh, M.D., MB, MMSc (age 49), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO, President & Director | Aoife M. Brennan BAO, BCh, M.D., MB, MMSc (age 49) |
|---|---|
| CFO & Principal Accounting Officer | Susan Altschuller (age 43) |
| Senior Vice President of Technical Operations | Adam Villa |
| Senior Vice President of People & Workforce Strategy | Ashley Jones |
Major Backers & Investors (CLYM)
Notable institutional backers of Climb Bio, Inc. include RA Capital Management, L.P., Fidelity, FMR, LLC, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 19.68% |
| Fidelity | 12.16% |
| FMR, LLC | 11.82% |
| UBS Group AG | 5.93% |
| Braidwell LP | 4.87% |
| Adage Capital Partners GP L.L.C. | 4.36% |
| Price (T.Rowe) Associates Inc | 3.7% |
| Cormorant Asset Management, LP | 3.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.67% |
| Vanguard Group | 5.34% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt